Mbd3l2, methyl-CpG-binding domain protein 3-like 2, is a protein-coding gene. It lacks the methyl-CpG-binding domain but is homologous to MBD2 and MBD3. It is involved in epigenetic regulation pathways, potentially influencing transcriptional modulation [2,4]. Mbd3l2 may play a role in processes related to DNA methylation and demethylation, which are crucial for normal development and disease-related gene regulation [1].

Gene knockout studies in mice showed that Mbd3l2 knockout mice were viable and fertile, suggesting that Mbd3l2 is dispensable for early development, fertility, and zygotic DNA demethylation in mice [3]. In another aspect, Mbd3l2 can promote Tet2 enzymatic activity, facilitating the conversion of 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC), with potential implications in cancer development as Tet2 mutations are common in human malignancies [1]. Also, Mbd3l2 interacts with MBD3 and components of the NuRD complex and can oppose MBD2-MeCP1-mediated methylation silencing, acting as a transcriptional modulator [2].

In summary, Mbd3l2 appears to have functions in epigenetic regulation, especially in relation to DNA methylation-associated processes. Although Mbd3l2 knockout mice show normal early development and fertility, its role in promoting Tet2 activity and modulating transcriptional repression provides insights into cancer-related epigenetic dysregulation, highlighting its importance in understanding disease mechanisms [1,2,3].